Nov 20, 2023
Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that Lawrence M.
Nov 10, 2023
Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)
Hepatitis B virus e antigen positive (HBeAg+) subjects dosed with once-daily 300mg ALG-000184 + entecavir for up to 48 weeks demonstrated: Dose dependent mean reductions of up to 2 log 10 IU/mL for HBV antigens Mean DNA reductions of up to 6.8 log 10 IU/mL No viral DNA breakthroughs in subjects
Nov 07, 2023
Aligos Therapeutics to Present Multiple Posters at AASLD’s The Liver Meeting® 2023, Highlighting Progress for Its Clinical Stage Portfolio, including Lead THR-β Agonist for the Treatment of NASH, ALG-055009; ALG-000184, the Company’s Lead CAM-E Molecule,
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that the company is
Oct 26, 2023
Aligos Therapeutics to Announce 3rd Quarter Results on November 2, 2023
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that announced that it will report
Oct 23, 2023
Aligos Therapeutics Announces $92 Million Private Placement Financing
Proceeds expected to fund the following: - NASH (ALG-055009): top line data from Phase 2a study (Q4 2024) - Hepatitis B/CAM-E (ALG-000184): Phase 2 enabling activities (H2 2024) - Funding expected to extend cash runway through end of 2025 SOUTH SAN FRANCISCO, Calif., Oct.
Displaying 1 - 10 of 29